An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
NCT02515279 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 463
Last updated 2017-04-10
Summary
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
Conditions
- Hepatitis C
Interventions
- DRUG
-
Peginterferon alfa-2a
180 micrograms subcutaneous weekly for 48 weeks.
- DRUG
-
Ribavirin
1000-1600 mg day orally for 48 weeks.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-11-30
- Primary Completion
- 2014-12-31
- Completion
- 2014-12-31
Countries
- Austria
More Related Trials
-
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
NCT02791256 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
NCT00800748 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
NCT01679834 ·Status: COMPLETED
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
NCT00087568 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
NCT01604291 ·Status: COMPLETED
-
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
NCT01750216 ·Status: COMPLETED
-
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
NCT01853254 ·Status: COMPLETED ·Phase: PHASE3
-
Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
NCT00087607 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.
NCT00087594 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
NCT01033448 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
NCT02761629 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
NCT01429792 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
NCT00077649 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
NCT00922779 ·Status: COMPLETED ·Phase: PHASE4
-
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
NCT01066793 ·Status: COMPLETED
-
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
NCT00122616 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
NCT00353418 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
NCT02731131 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
NCT00623428 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.
NCT00475072 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
NCT01296971 ·Status: WITHDRAWN ·Phase: PHASE3
-
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
NCT00077636 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
NCT01392742 ·Status: COMPLETED
-
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
NCT00800735 ·Status: COMPLETED ·Phase: PHASE3
-
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
NCT00087646 ·Status: COMPLETED ·Phase: PHASE4